Chronic Kidney Disease is a horrible public health issue that seriously impacts, and, thereis a significant unmet need for therapies that would slow down Disease Progression and Improve Outcomes.

Chronic kidney disease occurs when the kidneys are damaged and cannot filter blood normally. Due to this defective filtering, patients get complications related to fluid, electrolytes (minerals required for many bodily processes), and waste build-up in the body. Chronic kidney disease quite often accelerate progress to kidney failure. Patients also are at high risk of cardiovascular disease, including heart disease and stroke.

Recently, USFDA has approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. Its approval is an important step forward in helping people living with kidney disease.

World need therapies for Innovative Drugs to Target Renal Inflammation in Sepsis (RIS) and Acute Kidney Injury (AKI) because Sepsis-related mortality roughly doubles when acute kidney injury (AKI) occurs.

Kindman’s is committed to market Dapagliflozin and other drugs related RIS and AKI with and without combination soon. Furthermore, it will focus on its own research model to provide short and long terms therapies as well.

Kindman’s shall striveto put its Heart & Mind together on the therapies of Immunology and Oncologyafter some good work on the above 4 major Chronic Diseases Complications